Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) PT at $11.50

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned a consensus rating of “Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.50.

Several equities analysts recently commented on CATX shares. Bank of America cut their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Piper Sandler dropped their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. William Blair began coverage on shares of Perspective Therapeutics in a research report on Friday. They set an “outperform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX opened at $2.88 on Friday. The business’s 50 day moving average is $3.04 and its two-hundred day moving average is $3.65. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. On average, equities research analysts expect that Perspective Therapeutics will post -0.98 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Portland Investment Counsel Inc. bought a new position in Perspective Therapeutics in the second quarter worth $852,000. Bank of New York Mellon Corp acquired a new position in shares of Perspective Therapeutics in the 2nd quarter valued at $1,015,000. Taylor & Morgan Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 127.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after buying an additional 37,000 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Perspective Therapeutics during the 1st quarter worth about $1,581,000. Finally, Avidity Partners Management LP boosted its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.